IL247828A0 - Progesterone formulations - Google Patents

Progesterone formulations

Info

Publication number
IL247828A0
IL247828A0 IL247828A IL24782816A IL247828A0 IL 247828 A0 IL247828 A0 IL 247828A0 IL 247828 A IL247828 A IL 247828A IL 24782816 A IL24782816 A IL 24782816A IL 247828 A0 IL247828 A0 IL 247828A0
Authority
IL
Israel
Prior art keywords
progesterone formulations
progesterone
formulations
Prior art date
Application number
IL247828A
Other languages
Hebrew (he)
Inventor
Janice Cacace
Peter Persicaner
Thorsteinn Thorsteinsson
Frederick Sancilio
Julia Amadio
Brian Bernick
Original Assignee
Therapeuticsmd Inc
Janice Cacace
Peter Persicaner
Thorsteinn Thorsteinsson
Frederick Sancilio
Julia Amadio
Brian Bernick
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therapeuticsmd Inc, Janice Cacace, Peter Persicaner, Thorsteinn Thorsteinsson, Frederick Sancilio, Julia Amadio, Brian Bernick filed Critical Therapeuticsmd Inc
Publication of IL247828A0 publication Critical patent/IL247828A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IL247828A 2014-03-28 2016-09-14 Progesterone formulations IL247828A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461972068P 2014-03-28 2014-03-28
PCT/US2015/023041 WO2015148952A1 (en) 2014-03-28 2015-03-27 Progesterone formulations

Publications (1)

Publication Number Publication Date
IL247828A0 true IL247828A0 (en) 2016-11-30

Family

ID=54196452

Family Applications (1)

Application Number Title Priority Date Filing Date
IL247828A IL247828A0 (en) 2014-03-28 2016-09-14 Progesterone formulations

Country Status (10)

Country Link
EP (1) EP3122364A4 (en)
JP (2) JP2017509630A (en)
KR (1) KR20160137597A (en)
AR (1) AR099872A1 (en)
AU (1) AU2015237243A1 (en)
CA (1) CA2942568A1 (en)
IL (1) IL247828A0 (en)
MX (1) MX2016011706A (en)
RU (1) RU2016136666A (en)
WO (1) WO2015148952A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210386757A1 (en) * 2018-10-17 2021-12-16 Sarah S. Stadler Methods of Treating Menopausal Symptoms Using Low Dose Progesterone
CN112336699A (en) * 2019-08-09 2021-02-09 南京科宁检测科技有限公司 Progesterone vaginal slow-release soft capsule and its preparation method
US20220105107A1 (en) * 2020-10-01 2022-04-07 Michael Liguori Bioidentical progesterone cream infused with nanoemulsified cbd

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004504342A (en) * 2000-07-24 2004-02-12 ファルマシア・アンド・アップジョン・カンパニー Self-emulsifying drug delivery system for highly water-insoluble lipophilic drugs
EP1482946A1 (en) * 2002-03-14 2004-12-08 Watson Pharmaceuticals, Inc. Progesterone oral drug delivery system
ATE543489T1 (en) * 2005-05-26 2012-02-15 Teva Womens Health Inc ORAL DOSAGE FORMS CONTAINING PROGESTERONE AND METHODS OF USE AND MANUFACTURING THEREOF
US20110312927A1 (en) * 2010-06-18 2011-12-22 Satish Kumar Nachaegari Progesterone Containing Oral Dosage Forms and Related Methods
US20110312928A1 (en) * 2010-06-18 2011-12-22 Lipocine Inc. Progesterone Containing Oral Dosage Forms and Related Methods
US9301920B2 (en) * 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) * 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) * 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies

Also Published As

Publication number Publication date
EP3122364A4 (en) 2017-10-25
MX2016011706A (en) 2017-05-01
RU2016136666A3 (en) 2018-11-07
WO2015148952A1 (en) 2015-10-01
KR20160137597A (en) 2016-11-30
RU2016136666A (en) 2018-05-03
JP2017509630A (en) 2017-04-06
AU2015237243A1 (en) 2016-09-29
CA2942568A1 (en) 2015-10-01
AR099872A1 (en) 2016-08-24
JP2019206540A (en) 2019-12-05
EP3122364A1 (en) 2017-02-01

Similar Documents

Publication Publication Date Title
TWD174428S (en) Spatula
GB201407934D0 (en) Formulation
IL252062A0 (en) Transdermal formulations
ZA201701461B (en) Antibody formulations
GB201419261D0 (en) Formulations
GB201419091D0 (en) Formulations
GB201514758D0 (en) Formulation
IL247828A0 (en) Progesterone formulations
IL248835A0 (en) Ceritinib formulation
HUE054584T2 (en) Maropitant formulation
GB201407384D0 (en) Formulation
IL251362A0 (en) Formulation
GB201521771D0 (en) Formulation
GB201511301D0 (en) Formulation
GB201511255D0 (en) Formulation
GB201402448D0 (en) Novel formulation
GB201507784D0 (en) Formulations
GB201505532D0 (en) Formulations
SG11201609593RA (en) Phase-shifting formulations
GB201416536D0 (en) Formulation
GB201416274D0 (en) Formulation
GB201412754D0 (en) Formulation
GB201504662D0 (en) Formulation
GB201404773D0 (en) Formulation
GB201418555D0 (en) Pemetrexed formulations